Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors.
about
Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel diseaseInflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological TreatmentsQuantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assayAshkenazi Jewish origin protects against formation of antibodies to infliximab and therapy failure.Management of inflammatory bowel disease with oral serum-derived bovine immunoglobulin.Immunogenicity of Isogenic IgG in Aggregates and Immune Complexes.Evaluating and Reporting the Immunogenicity Impacts for Biological Products--a Clinical Pharmacology PerspectiveTNF blocking therapies and immunomonitoring in patients with inflammatory bowel diseaseControversies in Establishing Biosimilarity: Extrapolation of Indications and Global Labeling Practices.Biologic concentration testing in inflammatory bowel disease.Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?Systematic Review and Meta-Analysis: Serum Infliximab Levels During Maintenance Therapy and Outcomes in Inflammatory Bowel DiseaseTargeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients.Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease.Reversal of Immunogenicity in Inflammatory Bowel Disease.The Role of Aggregates of Therapeutic Protein Products in Immunogenicity: An Evaluation by Mathematical Modeling.The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World ExperienceSustained secretion of anti-tumor necrosis factor α monoclonal antibody from ex vivo genetically engineered dermal tissue demonstrates therapeutic activity in mouse model of rheumatoid arthritis.C-reactive protein as a predictor of low trough infliximab concentrations in patients who lose response to infliximab.Recombinant Proteins and Monoclonal Antibodies.IMPORTANCE OF MEASURING LEVELS OF INFLIXIMAB IN PATIENTS TREATING INFLAMMATORY BOWEL DISEASE IN A BRAZILIAN COHORT.Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.
P2860
Q26745721-2823E71F-E46A-4B43-8DF2-370F059A9455Q26785537-B77500EB-A27C-4618-92A1-208FBDD4A4CCQ33745965-53F7DDB2-2E00-4AC1-8049-F9F0E922338AQ36151324-C0722FAD-6B7D-41E1-A459-D755042BF89EQ36212191-0832E623-567F-4E8F-B38F-D62481DB4BA8Q36257660-EF7C4F0B-73F8-4731-B68F-54A96DE0A3A9Q36653930-83C31530-CB5E-4220-826D-CA06BB648D16Q38206507-F2B45A17-0EB1-4DEC-B2D5-659F8F2B5357Q38291910-F2EF090D-73D9-4A28-9D90-81CF0B89596BQ38319306-B9A94822-55DF-4FDD-B7D7-C8A5D4C7CDA3Q38631012-3F99F62C-5C7D-4C54-8699-1300502F0301Q38695700-909F3109-8D83-4108-97EA-54CDA74D4AB0Q39209120-6C562681-D304-4993-B633-2A9A925C6DCDQ39306418-B54F5DA5-A682-43BF-A168-04FCEFFD7888Q39748377-33A467D8-1E3B-4713-97B1-286F7520C659Q41882145-189CBC5B-46C7-4E24-8E45-486E0AE86C9CQ41953123-0D94A8C3-536B-44B9-ABE3-E055AD39B574Q42000636-E707974F-7BBA-4DAC-BCB4-C5DB10E3A263Q45869248-00E3F675-2893-4950-B8C6-8E7C8073F3F0Q47422402-CB15B792-89D9-4501-BDCA-2283D42A6975Q47602370-1F32AAD5-B1F6-4228-A184-C8A63E2EE17BQ47736134-CBCAB5D5-E3D1-47AB-B944-006F56FB1FDCQ51600613-21DAAFD2-BBFD-4CB0-9455-B6778418FFABQ55693561-E9C7C913-2198-423B-89E8-41D1EBA49C82
P2860
Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Review article: immunogenicity ...... roduct and prescriber factors.
@en
type
label
Review article: immunogenicity ...... roduct and prescriber factors.
@en
prefLabel
Review article: immunogenicity ...... roduct and prescriber factors.
@en
P2093
P2860
P356
P1476
Review article: immunogenicity ...... roduct and prescriber factors.
@en
P2093
P2860
P304
P356
10.1111/APT.12507
P407
P577
2013-10-03T00:00:00Z